<DOC>
	<DOCNO>NCT03052608</DOCNO>
	<brief_summary>A phase 3 study demonstrate whether lorlatinib give monotherapy superior crizotinib alone prolong progression-free survival advance ALK-positive NSCLC patient treatment naïve compare lorlatinib crizotinib respect overall survival population</brief_summary>
	<brief_title>A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis locally advance metastatic ALKpositive NSCLC ; least 1 extracranial measurable target lesion previously irradiate . CNS metastases allow asymptomatic currently require corticosteroid treatment . Availability archival FFPE tissue specimen . No prior systemic NSCLC treatment . ECOG PS 0 , 1 , 2 . Age ≥18 year . Adequate Bone Marrow , Liver , Renal , Pancreatic Function Negative pregnancy test female childbearing potential Spinal cord compression unless good pain control attain Major surgery within 4 week prior randomization . Radiation therapy within 2 week prior randomization , include stereotactic partial brain irradiation . Whole brain irradiation within 4 week prior randomization Active bacterial , fungal , viral infection Clinically significant cardiovascular disease , active within 3 month prior enrollment . Ongoing cardiac dysrhythmias , uncontrolled atrial fibrillation , bradycardia congenital long QT syndrome Predisposing characteristic acute pancreatitis last month prior randomization . History extensive , disseminate , bilateral presence Grade 3 4 interstitial fibrosis interstitial lung disease Active malignancy ( NSCLC , non melanoma skin cancer , situ cervical cancer , papillary thyroid cancer , LCIS/DCIS breast , localized prostate cancer ) within last 3 year prior randomization . Concurrent use follow food drug within 12 day prior first dose lorlatinib crizotinib . 1. know strong CYP3A inhibitor . 2. know strong CYP3A inducer 3. know P gp substrate narrow therapeutic index Concurrent use CYP3A substrates narrow therapeutic index within 12 day prior first dose lorlatinib crizotinib . Other severe acute chronic medical psychiatric condition , include recent active suicidal ideation behavior , laboratory abnormality may increase risk associate study participation interfere interpretation study result Investigational site staff member directly involved conduct study family member , Pfizer employee , include family member , directly involve conduct study . Participation study involve investigational drug ( ) within 2 week prior study entry and/or study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ALK ; anaplastic lymphoma kinase ; Non-Small-Cell Lung cancer ; NSCLC</keyword>
</DOC>